

ROSETTA  
GENOMICS



**Exhibit A**

*Appl. No. 10/604984  
Prelim Amdt dated 01/04/2005  
Reply to Notice of Oct 15 2004  
Page 1 of 3*

January 4, 2005

**Preliminary Amendment**

Appl. No. : 10/604984  
Applicant : Itzhak Bentwich  
Filed : 29-Aug-03  
Customer No. : 37808

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

In response to the Formalities Letter dated October 15, 2004 that mentions references to omitted drawings, please amend the above-identified application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.

**Amendments to the Specification:**

Please delete paragraph [0059], which begins with "Figs. 15A through 2739D are schematic diagrams..." and paragraph [0060], which begins with "Figs. 2740 through 3297 are schematic diagrams..."

Please replace paragraph [0056] with the following amended paragraph:

Fig. 13C is a picture of laboratory results, which confirm endogenous expression of bioinformatically detected novel gene GAM25 of Fig. ~~15A~~13A;

Please replace paragraph [0086] with the following amended paragraph:

The present invention discloses 2725 novel viral genes of the VGAM group of genes, which have been detected bioinformatically, as described hereinbelow with reference to Tables 1 and 2~~Figs. 15 through 2739~~. Laboratory confirmation of 4 genes of the GAM group of genes is described hereinbelow with reference to Figs. 12 through 14.

Please replace paragraph [0134] with the following amended paragraph:

The present invention discloses 3283 novel viral genes of the GR group of genes, which have been detected bioinformatically, as described hereinbelow with reference to Tables 1 and 2~~Figs. 15 through 3297~~. Laboratory confirmation of 3 genes of the GR group of genes is described hereinbelow with reference to Figs. 9A through 14.

Please replace paragraph [0137] with the following amended paragraph:

The present invention discloses a first plurality of novel genes referred to here as VGAM genes, and a second plurality of operon-like genes referred to here as GR genes, each of the GR genes encoding a plurality of VGAM genes. The present invention further discloses a very large number of known target-genes, which are bound by, and the expression of which is modulated by each of the novel genes of the present invention. Published scientific data referenced by the present invention provides specific, substantial, and credible evidence that the abovementioned target genes modulated by novel genes of the present invention, are associated with various diseases. Specific novel genes of the present invention, target genes thereof and diseases associated therewith, are described hereinbelow with reference to Tables 1 and 2~~Figs. 15 through 2739~~. It is therefore appreciated that a function of VGAM genes and GR genes of the present invention is modulation of expression of target genes related to known diseases, and that therefore utilities of novel genes of the present invention include diagnosis and treatment of the abovementioned diseases. Fig. 10 describes various types of diagnostic and therapeutic utilities of novel genes of the present invention.

**REMARKS/ARGUMENTS**

The amendments to the specification listed above are requested in order to cancel unintentional references in the original version of the specification to omitted drawings that were not included and not intended to be included in the original specification. Those references were redirected to Tables of the original version of the specification as was the initial intention of the inventor. One of the amendments (Paragraph 56) remedies an incorrect reference to a drawing within the Brief Description of Drawings.

All of the changes correct typographical errors that were entered unintentionally in the original submission.

No new matter has been included in the specification.

On behalf of Rosetta Genomics,



Yaffa Schindler

Rosetta Genomics LTD